Myeloid/Lymphoid neoplasms with abnormalities of PDGFRB by Lancaster-Shorts, Katrina L et al.
 Leukaemia Section 
Review 
Atlas Genet Cytogenet Oncol Haematol. 2018; 22(5) 200 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
OPEN ACCESS JOURNAL AT INIST-CNRS 
Myeloid/Lymphoid neoplasms with 
abnormalities of PDGFRB 
Katrina L. Lancaster-Shorts, Joanna Chaffin, Natasha M. Savage 
Department of Pathology, Augusta University, Augusta, GA, USA; nsavage@augusta.edu 
Published in Atlas Database: April 2017 
Online updated version : http://AtlasGeneticsOncology.org/Anomalies/MyeloLymphoPDGFRBID1745.html 
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/68902/04-2017-MyeloLymphoPDGFRBID1745.pdf 
DOI: 10.4267/2042/68902
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2018 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
Abstract 
This insert represents a review of myeloid and 
lymphoid neoplasms with abnormalities of 
PDGFRB including clinical presentation, 
morphologic review, and cytogenetic findings. 
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Clinics and pathology 
Disease 
Myeloid and lymphoid neoplasms with 
abnormalities of PDGFRB are neoplasms in which 
eosinophilia is typical, although not required. Gene 
fusions with PDGFRB were first described by Golub 
et al. in 1994 in a patient with features consistent 
with chronic myelomonocytic leukemia (CMML). 
Since that time, over 20 fusion partners have been 
described. The entity was first formally accepted in 
the 2008 edition of the World Health Organization's 
Classification of Tumours of Haematopoietic and 
Lymphoid Tissues along with abnormalities of 
PDGFRA and FGFR1. In the WHO 2016 edition, 
myeloid and lymphoid neoplasms with eosinophilia 
and t(8;9)(p22;p24.1) PCM1 / JAK2 is now 
recognized as a provisional entity. 
Phenotype/cell stem origin 
The cell of origin is a hematopoietic cell with 
commitment to eosinophilic differentiation. 
Epidemiology 
Myeloid and lymphoid neoplasms with eosinophilia 
and abnormalities of PDGFRB (as well as 
abnormalities of PDGFRA and FGFR1) are rare. 
Adult males are most commonly affected with a 
median age of onset in the late forties; however, 
older adults and rarely children have also been 
affected. 
Clinics 
Patients typically present with splenomegaly with 
hepatomegaly being less frequent; lymphadenopathy 
may also be seen. As with abnormalities of 
PDGFRA, skin and cardiac infiltration may be 
present at diagnosis with resulting cardiac damage. 
Pathology 
In patients with abnormalities of PDGFRB, 
peripheral blood and bone marrow are almost always 
involved with typical leukocytosis and possible 
concordant anemia and/or thrombocytopenia. 
Leukocytosis is usually predominated by 
monocytosis and eosinophilia imparting a chronic 
myelomonocytic leukemia (CMML)-like picture 
with eosinophilia (Figure 1 and 2). Eosinophils may 
have atypical morphology. Rarely, basophilia is also 
prominent. However, some patients present with 
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features more suggestive of atypical chronic myeloid 
leukemia without BCR / ABL1 (aCML) or chronic 
eosinophilic leukemia (CEL) or more rarely, they 
present with phenotypic features of acute 
lymphoblastic leukemia (ALL), acute myeloid 
leukemia (AML), or juvenile myelomonocytic 
leukemia (JMML). 
The bone marrow is typically hypercellular (Figure 
3) with accompanying fibrosis. As in cases with 
PDGFRA abnormalities, mast cell aggregates (not 
meeting criteria for systemic mastocytosis) can be 
seen. 
 
Monocytosis is seen along with atypical eosinophils with cytoplasmic vacuolation, uneven granule distribution, 
and increased nuclear lobes. (Wright Giemsa stained peripheral blood smear, original magnification 500x) 
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Leukocytosis is noted with increased monocytes and several blasts. In addition, an atypical eosinophil is noted 
with sparse uneven granule distribution. (Wright Giemsa stained peripheral blood smear, original magnification 
1000x) 
 
 
A markedly hypercellular bone marrow with myeloid hyperplasia including many eosinophils is appreciated. 
(Hematoxylin and Eosin stained bone marrow biopsy, original magnification 500x) 
Treatment 
Patients with abnormalities of PDGFRB are 
exquisitely sensitive to imatinib, like patients with 
abnormalities of PDGFRA, and this is the drug if 
choice. Primary and secondary resistance is 
uncommon; initial response typically occurs within 
2 months. 
Prognosis 
Previously, this neoplasm was cited as an aggressive 
disease with a median overall survival of less than 2 
years. However, after the universal initiation of 
imatinib as standard therapy, a recent study cited a 
10-year overall survival of 90% (Cheah et al., 2014). 
Cytogenetics 
Myeloid/Lymphoid neoplasms with 
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G-banded karyotype demonstrating 46,XY,t(5;12)(q33.1;p13.2). 
Cytogenetics morphological 
PDGFRB can have a variety of fusion partners with 
more than 20 currently described (Table 1), but by 
far the most common fusion is ETV6-PDGFRB. 
Conventional karyotyping usually readily identifies 
5q33 (PDGFRB) rearrangements (Figure 4). 
Multicolor FISH has also been useful in recognizing 
PDGFRB rearrangements or confirming suspected 
fusion on karyotype by using probes that closely 
flank both ends of the gene. 
Fusion partner genes and locations 
ETV6 12p12  
CCDC88C 14q32  
CCDC6 10q21  
TRIP11 14q32  
TPM3 1q21  
CAPRIN1 1p11  
GIT2 12q24  
RABEP1 17p13  
CEP85L  6q22  
PRKG2 4q21  
COL1A1 17q21  
NDE1 16p13  
SPTBN1 2p21  
PDE4DIP 1q21  
TP53BP1 15q15-q21  
SPECC1 17p11  
GOLGA4 3p22  
HIP1 7q11  
BIN2 12q13  
MYO18A 17q11  
NIN 14q22  
SART3 12q23  
ERC1 12p13  
WDR48 3p21  
DTD1 20p11  
KANK1 9p24  
 
Genes involved and 
proteins 
PDGFRB (platelet-derived growth 
factor receptor, beta polypeptide) 
Location 
5q32 
Note 
Platelet Derived Growth Factor Receptor Beta 
(PDGFRB) is located on chromosome 5, band q32. 
It contains 23 exons and spans approximately 149.5 
Mb. The encoded protein is 1067 amino acids. As 
with PDGFRA, it is a member of the type III class of 
tyrosine kinase receptors. 
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Result of the chromosomal 
anomaly 
Hybrid gene 
Note 
The most common fusion gene produced is the 
ETV6 /PDGFRB, due to t(5;12)(q31~33;p13), 
which is typically detected via conventional 
karyotyping. However, many fusion partners are 
described as PDGFRB is known to be the most 
promiscuous of all of the genes involved in myeloid 
and lymphoid neoplasms with eosinophilia (and 
abnormalities of PDGFRA, PDGFRB, or FGFR1). 
This fusion gene produces an activated tyrosine 
kinase that transforms hematopoietic cells due to 
constitutive activation. 
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